(Press-News.org) The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found.
The findings published in the journal Cancer Research show that the drugs kill cancer cells in a completely new way.
Early stage clinical trials of the drugs in elderly patients with acute myeloid leukaemia (AML) have shown promising results, with survival three months longer on average than standard palliative care. The combination, known as BaP, has also been used alongside chemotherapy to successfully treat children with Burkitt's lymphoma (BL), the most common childhood cancer in Eastern Africa.
Until now it was uncertain whether the activity of the drugs against these two very different blood cancers was mediated by a common mechanism or by different effects in each cancer type.
The scientists, who were funded by Leukaemia & Lymphoma Research, used state of the art technology to interrogate the drug's effects on the metabolism and chemical make-up of AML and BL cells and found that in both cell types the drugs block an enzyme crucial to the production of fatty acids, which cancer cells need to grow and multiply. They also demonstrated that the ability of BaP treatment to deactivate this enzyme, called stearoyl CoA desaturase, was what prompted cancer cells to die.
The findings open up the possibility that BaP could be used to treat many other types of cancer that also rely on high levels of stearoyl CoA desaturase to grow. These cancers include chronic lymphocytic leukaemia, some types of non-Hodgkin lymphoma, as well as prostate, colon and oesophageal cancer.
The team now hope that the BaP combination will be tested in new clinical trials later this year for patients with an aggressive set of blood disorders known as myelodysplastic syndromes.
Dr Andrew Southam, the lead scientist on the research at the University of Birmingham, said, "Developing drugs to target the fatty acid building blocks of cancer cells has been a promising area of research in recent years. It is very exciting we have identified these non-toxic drugs already sitting on pharmacy shelves."
The 'redeployment' of low toxicity drugs originally developed to treat other conditions has had considerable success in recent years in the blood cancer field. Thalidomide has become part of standard treatment for the bone marrow cancer myeloma. All trans retinoic acid (ATRA), originally an acne medication, has transformed survival rates for patients with a particularly aggressive type of leukaemia to over 80%. Drugs already in medical use do not need to be tested again in early stage clinical trials and are also much cheaper than new cancer drugs.
Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, worked on the project at the University of Birmingham. He said, "This drug combination shows real promise. Affordable, effective, non-toxic treatments that extend survival, while offering a good quality of life, are in demand for almost all types of cancer. Patients tend to be elderly and often cannot tolerate the toxic side-effects of traditional chemotherapy."
INFORMATION:
Alexandria, VA - The evolutionary age of grass has been hotly contested. Scientists have previously dated the earliest grasses to 55 million years ago; after the dinosaurs went extinct. Now, a new 100-million-year-old specimen of amber from Myanmar potentially pushes back grass evolution to the Late Cretaceous.
Scientists from the Oregon State University who studied the amber believe they identified "spikelet" - grass in its flowering state - and a cluster of fossilized ergot, a major ingredient in LSD. While their conclusions are intriguing, and have implications for ...
The knock-on effects of the economic downturn have been explored in economy and psychology. Now researchers are examining the effects of unemployment on an even darker subject - cancer mortality.
One would think that dealing with unemployment was challenge enough. But according to the latest research published in ecancermedicalscience, rises in unemployment are associated with significant increases in prostate cancer mortality.
This is the first study that has systematically explored the consequences that changes in unemployment - in particular the Great Recession ...
ALEXANDRIA, Va. - The American Society of Clinical Oncology (ASCO) today announced results from four major studies to be presented at ASCO's 51st Annual Meeting, May 29-June 2, in Chicago. Findings showed that use of a widely available vitamin pill reduces the risk of non-melanoma skin cancers; that early chemotherapy extends the lives of men with advanced prostate cancers; and that new therapies can improve outcomes for children with a rare form of kidney cancer and adults with relapsed multiple myeloma.
The studies are among the around 5,000 abstracts publicly released ...
WASHINGTON - A special issue of American Psychologist provides a comprehensive review of over 40 years of research on bullying among school age youth, documenting the current understanding of the complexity of the issue and suggesting directions for future research.
"The lore of bullies has long permeated literature and popular culture. Yet bullying as a distinct form of interpersonal aggression was not systematically studied until the 1970s. Attention to the topic has since grown exponentially," said Shelley Hymel, PhD, professor of human development, learning and culture ...
LOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.
The tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.
Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function. The new blood tests identify the ...
Researchers have published results in Environmental Research Letters confirming strong warming in the upper troposphere, known colloquially as the tropospheric hotspot. The hot has been long expected as part of global warming theory and appears in many global climate models.
The inability to detect this hotspot previously has been used by those who doubt man-made global warming to suggest climate change is not occurring as a result of increasing carbon dioxide emissions.
"Using more recent data and better analysis methods we have been able to re-examine the global weather ...
A new report by the Nuffield Council on Bioethics calls for a change in culture across all areas of children's health research, so that children's and young people's views and opinions can help to shape how research is prioritised, designed and reviewed. Unless ethical concerns about asking children to take part in research are addressed, our understanding of childhood disorders and ability to provide evidence based care will remain limited.
"It will always be easier to say 'no' to research with children on the grounds that it's too difficult, but we should challenge ...
A new Australian study shows that cells which form the bulk of our fast-acting 'innate' immune system behave differently, depending on whether an injury is infected or not.
It is well known that paparazzi-like 'neutrophils' swarm to sites of injury within minutes to undertake damage control and kill invaders. Most have very short lives and self-destruct once their job is done.
Sydney researchers now demonstrate that in certain cases neutrophils can also enlist reinforcements in their fight against pathogens. If the injury is infected, neutrophils seek out accomplices ...
A ground-breaking discovery by Monash University researchers could revolutionise treatments given to lupus sufferers, saving thousands of people each year from serious illness or death caused by secondary infections.
Lupus is a vicious and widespread autoimmune disease that can attack any part of the body. It affects one in 1,000 Australians and 5 million people worldwide, and its victims are typically young women. Indigenous and Asian people suffer higher rates than other groups.
Current treatments for lupus essentially 'switch off' the patient's immune system to stop ...
This news release is available in Spanish.
Compelling clinical activity of PM1183 in second line, achieving 67% response rate and a progression-free survival of 4.7 months in patients with small cell lung cancer (SCLC), a type of tumor with very limited treatment alternatives
Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS® in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation
Phase 2 data showcase activity of YONDELIS® in malignant pleural mesothelioma, a rare form of lung cancer that is largely related ...
